Neurocrine Biosciences | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Cytokinetics USD 179.67M 69.86M 2024-12
Dynavax Technologies USD 78.63M 8.6M 2024-12
Exelixis USD 403.77M 9.42M 2025-01
Gilead Sciences USD 12B 279M 2024-12
Halozyme Therapeutics USD 139.1M 30.28M 2024-12
Incyte USD 1.64B 140.2M 2024-12
Intra Cellular Therapies USD 205.7M 39.59M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Pfizer USD 43B 216M 2024-12
Prothena USD 48.5M 2.08M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Repligen USD 108.37M 65.94M 2024-09
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Teva Pharmaceutical Industries USD 12.8B 1B 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Neurocrine Biosciences Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.